Immuno-Oncology

Updates to the NCCN guidelines for patients with resectable early-stage NSCLC now include neoadjuvant and adjuvant regimens with chemotherapy, immunotherapy, and targeted therapies, which promise to change biomarker testing practice.

Patients with cancer were reported to have mixed expectations with immunotherapy as part of their oncology treatment.

Oncology nurses found that the use of a flexible catheter for subcutaneous immunotherapy is linked with increased safety and satisfaction.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

An improved progression-free survival benefit was observed in patients with stage III unresectable or stage IV melanoma who received nivolumab plus ipilimumab.

An update from the phase 3 SKYSCRAPER-02 trial found that tiragolumab to atezolizumab did not significantly improve progression-free survival in extensive-stage small cell lung cancer.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

Nivolumab combined with chemotherapy is now approved in the resectable non–small cell lung cancer setting.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

A City of Hope expert underscores the benefit of using antibody-drug conjugates, CDK4/6 inhibitors, PARP inhibitors, and checkpoint blockade in early-stage and metastatic breast cancer.

Mark Honor, PA-C, highlights best adverse event management practices for patients undergoing chemotherapy and immune-based treatment.

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

Patient-reported outcomes demonstrated that nivolumab plus cabozantinib was associated with improved quality of life, while sunitinib was associated with health-related deterioration, in treatment-naïve renal cell carcinoma.

New data suggest that patients undergoing immunotherapy achieved better survival outcomes after reporting cutaneous immune-related adverse events.

Pending FDA approval, the dual immunotherapy combination could provide patients with a new treatment option which would not require any further safety requirements prior to initiation.

New data support increased fiber consumption and decreased probiotic use among patients receiving immunotherapy.

A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.

A novel regimen of relatlimab, an LAG-3 inhibitor, plus nivolumab doubled progression-free survival in patients with untreated, advanced melanoma.

Event co-chair, Syma Iqbal, MD, discusses key points from a recent OncLive® Institutional Perspectives in Cancer webinar, which focused on the evolving landscapes in gastrointestinal cancer.

A seroconversion rate of 94% was identified in a diverse cohort of patients with cancer who had received the COVID-19 vaccine.

Nivolumab with or without ipilimumab improved survival over ipilimumab alone in patients with previously untreated advanced melanoma.

New immunotherapy combinations are being explored in the small cell lung cancer space.

An expert gives an overview of recent advancements in the lung cancer space.

Chronic immune-related adverse effects arising from adjuvant anti–PD-1 therapy in patients with high-risk melanoma are more common than previously recognized, and often persisted with longer follow-up.

Namrata (Neena) Vijayvergia, MD, discusses the emerging role of immunotherapy in resectable and metastatic esophageal and gastric cancers, as well as key nuances that could complicate these agents’ utility in clinical practice.

Edgardo Santos, MD, FACP, discusses advances made with immunotherapy regimens in the first-line treatment of patients with metastatic non–small cell lung cancer and areas of active investigation.

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Immunotherapy continues to improve upon the treatment of non-small cell lung cancer, and there are more exciting advancements on the horizon.